Federal Advocacy

The Hospital and Healthsystem Association of Pennsylvania advocates on behalf of its members, educating state and federal lawmakers and policymakers about the health care delivery system and the countless health care issues that impact hospitals, patients, and communities.

Federal Legislative Priorities

HAP works with national health care organizations—particularly the American Hospital Association—and national coalitions to ensure federal policy supports Pennsylvania hospitals as they transform the health care system to improve patient care. HAP spearheads an informal coalition of more than 30 Pennsylvania health care provider organizations that work together to advance policy goals consistent with a shared commitment to promoting coverage and improving health outcomes for the citizens of Pennsylvania. 
 

Hospitals Support Safe Workplaces

HAP supported state reforms enacted during 2020 that made it a felony to assault a health care worker and protected health care workers’ identities by allowing their last names to be omitted from ID badges. At the federal level, HAP supports the SAVE Act, introduced by U.S. Representative Madeleine Dean (D-4), which would make assaulting a health care worker a federal crime and provide grants to help hospitals improve safety.
 

Medicaid Disproportionate Share Hospital (DSH) Program Cuts

The Medicaid Disproportionate Share Hospital (DSH) program provides payments to hospitals that serve a high proportion of Medicaid beneficiaries and uninsured patients. The payments are essential for hospitals to offset their uncompensated care costs from treating low-income patients. A series of payment cuts are scheduled for Fiscal Years 2020 through 2025, beginning with a $4 billion reduction during 2020. HAP opposes the deep payment cuts, which if put in place, would reduce Pennsylvania’s Medicaid DSH allotment by approximately $242 million during FY 2020. 
 

Preserving Payments for Legitimate Differences Between Sites of Care

A recent payment policy issued by the Centers for Medicare & Medicaid Services (CMS) expands the application of so-called “site-neutral” payments, cutting the payments hospitals receive for outpatient clinic visits.

So-called “site-neutral” payments policies reimburse hospitals for services across various sites of services at payment levels irrespective of the critical role hospitals play in our health care system—providing emergency standby services and specialized services such as trauma, psychiatric, obstetrics, and pediatric emergency care; treating more vulnerable patients; adhering to strict regulatory requirements that protect health and safety; and serving as the backbone of our emergency preparedness infrastructure.

The hospital community challenged the payment policy and a federal judge has ruled in favor of the American Hospital Association and other hospital plaintiffs, saying CMS did not have the authority to implement these new site-neutral payment cuts. Despite the judge's ruling, the 2020 final rule for the Medicare Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System and quality reporting programs retained a two-year phase-in of the “site neutral” policy. The rule takes effect January 1, 2020.
 

340B Drug Pricing Program

The 340B Drug Pricing Program helps hospitals that care for large numbers of uninsured and low-income patients and serve rural communities to manage the impact of high cost drugs by purchasing discounted medications from drug manufacturers. Savings are used to increase access to care or help patients secure prescription drugs at significantly reduced costs, or no cost at all. A 2018 Medicare regulation implemented reductions in the amount of the savings hospitals can recoup and reinvest in health care. The 2020 final rule for the Medicare Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System and quality reporting programs continues to reduce hospital reimbursement by maintaining a nearly 30 percent pay cut to certain participants in the federal 340B Drug Pricing Program, despite a federal judge's ruling against the reductions during both 2018 and 2019. HAP opposes the reductions that undercut the value of a crucial program helping hospitals and patients manage the burden of high prescription drug costs.

Get more details about these federal priorities and other key health care issues at the HAP Resource Center.
 

HAP Contacts

For more information, contact John Myers, vice president, federal advocacy. Media inquiries should be directed to  Liam Migdail, vice president, strategic communications.

 

HAP News


October 02, 2024

J&J Reverses Plan for 340B Drug Rebate

Johnson and Johnson (J&J) announced this week it was forgoing a controversial plan to offer rebates for certain 340B drugs instead of direct drug discounts.

+